Drug Trial Radar · NCT05251636
Adjunct Episcleral Brachytherapy for PCV
Last checked: Nov 20, 2026Latest source record: Aug 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
159
Planned (sponsor's estimate)
Start
Mar 2025
Primary completion
Sep 2026
Study completion Sep 2028
Sponsor
- Lead sponsor
- Salutaris Medical Devices, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is investigating the use of episcleral brachytherapy (ESB) adjunct to aflibercept compared to aflibercept monotherapy for the treatment of polyploid choroidal vasculopathy (PCV) in patients experiencing an inadequate response to anti-VEGF monotherapy.
Conditions
- Age-Related Macular Degeneration
- Polypoid Choroidal Vasculopathy
Interventions
Episcleral BrachytherapyRadiation
Minimally invasive, single fraction brachytherapy
Aflibercept InjectionDrug
Standard of Care intravitreal aflibercept injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Best Corrected Visual Acuity (BCVA)Time frame: 12 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.